对于COPD和COPD恶化的多特征多基因评分涉及可用药物的蛋白质
Chengyue Zhang1, Iain R Konigsberg2, Yixuan He3
1Channing Division of Network Medicine, Mass General Brigham, Boston, United States of America.
JCI insight
|February 19, 2026
概括
一个新的多特征多基因评分 (PRS) 提高了慢性阻塞性肺病 (COPD) 和恶化的预测. 这种方法还确定了COPD管理中的精准医学的潜在药物点.
科学领域:
- 遗传学和生物信息学 遗传学和生物信息学
- 肺部病理学 肺部病理学
- 药物基因组学 药物基因组学
背景情况:
- 慢性阻塞性肺病 (COPD) 对健康造成重大负担,需要改进预测和管理策略.
- 目前对COPD及其恶化的预测模型在准确性和范围上有局限性.
- 确定新的治疗点对于推进COPD精准医学至关重要.
研究的目的:
- 开发和验证多特征多基因评分 (PRSmulti) 以预测COPD和恶化风险.
- 评估PRSmulti在不同人群中的表现.
- 为了确定PRS相关的蛋白质,用于潜在的COPD治疗向.
主要方法:
- 利用PRSmix+框架,从COPDGene队列中的7个选定的特征构建一个复合PRS (PRSmulti).
- 在多个大,多样化的队列 (COPDGene,ECLIPSE,MassGeneral Brigham Biobank,我们所有人) 中,与COPD状态和恶化频率存在多种关联.
- 采用用GWAS数据的蛋白质预测模型和COPDGene和英国生物库的蛋白质数据验证的发现,以确定与PRS相关的蛋白质.
主要成果:
- 在元分析中,PRSmulti与COPD状态 (OR 1.58) 和恶化频率 (β 0.21) 有显著的关联.
- 与传统的单一特征PRS相比,PRSmulti在所有测试的队列中显示出优异的预测性能.
- 确定了73种与PRS相关的蛋白质,其中25种与现有或正在研究的药物有关,包括诸如RAGE/sRAGE,IL1RL1和SCARF2.2之类的显著标.
结论:
- 多特征PRS提供了一种可靠的方法来改善COPD和恶化风险的预测.
- 通过将PRS与蛋白质组数据集成,成功地确定了可用药物的蛋白质标.
- 这种方法代表了开发COPD个性化药物干预措施的有希望的战略.
相关概念视频
COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
